David A. Siegel Travere Therapeutics, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TVTX
# of Institutions
193Shares Held
84.6MCall Options Held
776KPut Options Held
900K-
Armistice Capital, LLC New York, NY7.65MShares$148 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$148 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$134 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$90.8 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$84.1 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.24B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...